Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain zapper could ease Parkinson's without surgery

NCT ID NCT07480317

Symptom relief Sponsor: Jiangsu Province Nanjing Brain Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new, non-invasive brain stimulation technique called temporal interference stimulation (TIS) for people with Parkinson's disease. The device uses electrodes on the scalp to send electrical currents deep into the brain, aiming to improve movement problems without the need for surgery. The trial will involve 75 participants with mild to moderate Parkinson's and will look at both immediate and long-term effects on motor and non-motor symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Temporal Interference Stimulation (TIS) device
What this could lead to
If it works, this could offer a non-invasive alternative to deep brain stimulation for managing Parkinson's motor symptoms.
What could go wrong
This is an early-stage trial with only 75 participants. The treatment is short-term (2 weeks), and long-term benefits or risks are unknown. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with Parkinson's Disease according to the Movement Disorder Society (MDS) clinical diagnostic criteria. * Hoehn \& Yahr Stage I-III (mild to moderate severity). * Aged 45 to 65 years. * Right-handed. Stable medication regimen for at least 1 hour before Phase A fMRI sessions and agreement to maintain a stable dosage during the 2-week Phase B intervention (unless clinically necessary). * Able to provide informed consent by the participant or a legal guardian. Exclusion Criteria: * MRI contraindications, such as implanted DBS electrodes, cardiac pacemakers, or other metal implants. * Significant cognitive impairment (MoCA score \< 24) or severe psychiatric symptoms. * History of epilepsy or structural brain lesions, including severe cerebral atrophy or cerebrovascular disease. * Severe head tremors that would interfere with MRI scanning quality.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanjing Brain Hospital (Affiliated Brain Hospital of Nanjing Medical University)

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.